login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
AN2 THERAPEUTICS INC (ANTX) Stock News
USA
-
Nasdaq
- NASDAQ:ANTX -
US0373261058
-
Common Stock
1.065
USD
-0.01 (-0.47%)
Last: 12/4/2025, 8:04:21 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
ANTX Latest News, Press Relases and Analysis
All
Press Releases
23 days ago - By: AN2 Therapeutics, Inc.
AN2 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business and Scientific Highlights
25 days ago - By: AN2 Therapeutics, Inc.
AN2 Therapeutics Announces Research Collaboration With GSK to Advance Boron-Based LeuRS-Inhibitors Targeting Tuberculosis (TB)
a month ago - By: AN2 Therapeutics, Inc.
AN2 Therapeutics to Participate in Fireside Chat at Evercore HealthCONx Conference
2 months ago - By: Benzinga
- Mentions:
SNGX
CHEK
ADAP
AYTU
...
12 Health Care Stocks Moving In Tuesday's After-Market Session
a year ago - By: Benzinga
- Mentions:
CIA
RPHM
Citizens And 2 Other Penny Stocks Insiders Are Buying
a year ago - By: InvestorPlace
ANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q2 2024
4 months ago - By: AN2 Therapeutics, Inc.
AN2 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business and Scientific Highlights
4 months ago - By: AN2 Therapeutics, Inc.
AN2 Therapeutics Commences First-in-Human Clinical Trial of Oral AN2-502998 for Chagas Disease
5 months ago - By: AN2 Therapeutics, Inc.
AN2 Therapeutics and DNDi Collaborate on Clinical Development of Promising New Oral Compound to Treat Chronic Chagas Disease
5 months ago - By: AN2 Therapeutics, Inc.
AN2 Therapeutics Reports Key Insights from 200-Patient Observational Study in Acute Melioidosis, Laying Groundwork for Phase 2 Proof-of-Concept Trial of Epetraborole
a year ago - By: BusinessInsider
ANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q2 2024
6 months ago - By: AN2 Therapeutics, Inc.
AN2 Therapeutics Announces Poster Presentation Highlighting M. Abscessus Data at 2025 Colorado Mycobacteria Conference
7 months ago - By: AN2 Therapeutics, Inc.
AN2 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business and Scientific Highlights
7 months ago - By: AN2 Therapeutics, Inc.
AN2 Therapeutics Reports Data from the Phase 3 Portion of Previously Terminated EBO-301 Study and Outlines Future Milestones from Boron Chemistry Pipeline
a year ago - By: InvestorPlace
Why Is AN2 Therapeutics (ANTX) Stock Down 35% Today?
2 years ago - By: BusinessInsider
ANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q1 2024
2 years ago - By: InvestorPlace
ANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q1 2024
7 months ago - By: AN2 Therapeutics, Inc.
AN2 Therapeutics to Participate in Citizens JMP Life Sciences Conference
8 months ago - By: AN2 Therapeutics, Inc.
AN2 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business and Scientific Highlights
9 months ago - By: AN2 Therapeutics, Inc.
AN2 Therapeutics to Present at Leerink Partners Global Healthcare Conference
9 months ago - By: AN2 Therapeutics, Inc.
AN2 Provides Strategic Update for Phase 3 EBO-301 Trial in Treatment Refractory MAC Lung Disease
10 months ago - By: AN2 Therapeutics, Inc.
AN2 Therapeutics to Participate at Upcoming Investor Conferences
10 months ago - By: AN2 Therapeutics, Inc.
AN2 Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
a year ago - By: AN2 Therapeutics, Inc.
AN2 Therapeutics to Participate at Upcoming Investor Conferences
a year ago - By: AN2 Therapeutics, Inc.
AN2 Therapeutics Reports Third Quarter 2024 Financial Results, Provides Important EBO-301 Update and Highlights Progress Across Boron Chemistry Pipeline
a year ago - By: AN2 Therapeutics, Inc.
AN2 Therapeutics Receives Continuation Grant to Discover Novel Boron Based Therapies for Tuberculosis (caused by Mycobacterium tuberculosis) and Malaria
a year ago - By: AN2 Therapeutics, Inc.
AN2 Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
a year ago - By: AN2 Therapeutics, Inc.
AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan
a year ago - By: AN2 Therapeutics, Inc.
AN2 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business and Scientific Highlights
a year ago - By: InvestorPlace
- Mentions:
AVD
BBLG
BW
CMND
...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
a year ago - By: AN2 Therapeutics, Inc.
AN2 Therapeutics Provides Update on EBO-301 Phase 2/3 Study Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium Complex (MAC) Lung Disease
2 years ago - By: AN2 Therapeutics, Inc.
AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights
Please enable JavaScript to continue using this application.